Abstract: Slide Presentations |


Seok Chul Yang, MD*; Young Whan Kim, MD; Chul-Gyu Yoo, MD; San Min Lee, MD; Choon-Taek Lee, MD; Sung Koo Han, MD; Young-Soo Shim, MD; Jae-Jun Lim, MD; Sven Hillinger, MD; Li Zhu, MD; Steven M. Dubinett, MD; Sherven Sharma, PhD
Author and Funding Information

Seoul National University, Seoul, South Korea


Chest. 2007;132(4_MeetingAbstracts):458b. doi:10.1378/chest.132.4_MeetingAbstracts.458b
Text Size: A A A
Published online


PURPOSE: Interleukin (IL)-7 is a pleiotropic, non-redundant cytokine necessary for the development of B and T lymphocytes, in particular gamma delta T cell receptor-positive cell differentiation. The cytokine can function as a cofactor during myelopoiesis and the generation of cytotoxic T cells and natural killer cells, can activate monocytes/macrophages, and support the survival of mature T cells. Tumor-induced immune suppression has been well documented in lung cancer and other malignancies. Tumor-reactive T cells accumulate in lung cancer tissues but fail to respond, in part, because high proportions of non-small cell lung cancer (NSCLC) TIL are Treg cells. T regulatory cells have a significant impact on the host response to cancer and defining the pathways that attenuate Treg activities in cancer bearing hosts may enhance anti-tumor immune responses.

METHODS: We evaluate the mechanisms of anti-tumor response to systemic IL-7 treatment in the immune competent tumor bearing mice.

RESULTS: In this study we show that systemic administration of IL-7 to tumor bearing mice reduced the frequency and activity of Treg cells, enhanced T cell lytic activity against the parental tumor and decreased tumor burden. IL-7 treatment of tumor bearing mice significantly reduced the apoptosis rates in the T cell population compared to diluent tumor bearing mice. Transfer of Treg cells to IL-7 treated tumor bearing mice partially reversed the anti-tumor effects of IL-7.

CONCLUSION: We conclude that IL-7 can down regulate Treg cell activity and enhance anti-tumor responses in vivo.

CLINICAL IMPLICATIONS: The potent anti-tumor properties demonstrated in this model provide a strong rationale for additional evaluation of IL-7 regulation of tumor immunity and its use in immunotherapy for lung cancer.

DISCLOSURE: Seok Chul Yang, No Financial Disclosure Information; No Product/Research Disclosure Information

Tuesday, October 23, 2007

10:30 AM - 12:00 PM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
Second Primary Tumors Involving Non-small Cell Lung Cancer*: Prevalence and Its Influence on Survival
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543